



**AmoyDx<sup>®</sup> Pan Lung Cancer PCR Panel  
Approved in Japan as a Companion Diagnostic  
for AUGTYRO<sup>®</sup> (repotrectinib)**

TOKYO and XIAMEN, September 25th, 2024 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd., (“AmoyDx”) and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx<sup>®</sup> Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic (CDx) for AUGTYRO<sup>®</sup> (repotrectinib) for patients with unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with *ROS1* fusion gene. AUGTYRO<sup>®</sup> is a product of Bristol-Myers Squibb K.K., and will be marketed in a 40 mg capsule dosage form.

Engineered using cutting-edge PCR technology, the AmoyDx<sup>®</sup> PLC Panel enables the simultaneous detection of activation alterations across 11 critical driver genes (*EGFR*, *ALK*, *ROS1*, *KRAS*, *BRAF*, *HER2*, *RET*, *MET*, *NTRK1*, *NTRK2*, *NTRK3*) and identifies actionable mutations in seven of these genes (*EGFR*, *ALK*, *ROS1*, *BRAF*, *MET*ex14 skipping, *KRAS*, *RET*) directly linked to sixteen targeted NSCLC therapies. This approval signifies a transformative step forward in precision cancer treatment, combining rapid, sensitive detection with the potential to significantly enhance patient outcomes.

“With this approval, the AmoyDx<sup>®</sup> PLC Panel can be used as a CDx to identify advanced NSCLC patients with *ROS1* fusion for treatment with Repotrectinib, thereby expanding their therapeutic options.” said Kenji Iwakabe, President and Chief Executive Officer of Riken Genesis, Li-Mou Zheng, Ph.D., Founder and Chairman of AmoyDx and Wenn Sun, Ph.D., Founder and President of PREMIA.

**About AmoyDx PLC Panel:**

(1) Product name	AmoyDx® Pan Lung Cancer PCR Panel
(2) Approval No.	30300EZX00069000
(3) Purpose of use	<p>Detection of <i>EGFR</i> gene mutations, <i>ALK</i> fusion gene, <i>ROS1</i> fusion gene, <i>BRAF</i> gene mutations, <i>MET</i>ex14 skipping mutation, <i>KRAS</i> gene mutations and <i>RET</i> fusion genes in nucleic acids extracted from cancer tissue.</p> <p>Used as an adjunct to determine the indications of the following sixteen antineoplastic agents for patients with NSCLC.</p> <ul style="list-style-type: none"> <li>• <b><i>EGFR</i> gene mutation</b> Gefitinib, Erlotinib hydrochloride, Afatinib maleate and Osimertinib mesylate</li> <li>• <b><i>ALK</i> fusion gene</b> Crizotinib, Alectinib hydrochloride and Brigatinib</li> <li>• <b><i>ROS1</i> fusion gene</b> Crizotinib, Entrectinib and Repotrectinib</li> <li>• <b><i>BRAF</i> V600E mutation</b> Combined administration of Dabrafenib mesylate and Trametinib dimethyl sulfoxide</li> <li>• <b><i>MET</i> exon 14 skipping mutation</b> Tepotinib, Capmatinib and Gumarontinib hydrate</li> <li>• <b><i>KRAS</i> G12C mutation</b> Sotorasib</li> <li>• <b><i>RET</i> fusion gene</b> Selpercatinib</li> </ul>
(4) Testing method	Real-time PCR
(5) Sample	FFPE tissue and fresh frozen tissue in which the presence of tumor cells was confirmed
(6) Package size	12 tests / kit
(7) Marketing Authorization Holder	Riken Genesis Co., Ltd.
(8) Manufacturer	Amoy Diagnostics Co., Ltd.

### **About Riken Genesis Co., Ltd.**

RIKEN GENESIS, founded in October 2007, provides lab-assay services as well as products for genetic testing based on cutting-edge gene analysis technologies and bioinformatics, and has experience in the field of personalized medicine. The company provides highly reliable tests based on international quality standards, as demonstrated by its CLIA certification, being the first organization in Japan to meet this U.S. quality control standard for clinical laboratories. For more information, please visit [www.rikengenesis.jp](http://www.rikengenesis.jp)

### **About Amoy Diagnostics Co., Ltd. (AmoyDx, SZSE: 300685)**

AmoyDx is at the forefront of championing molecular diagnostics for cancer, committed to enhancing patient outcomes worldwide through innovative diagnostic solutions and breaking barriers for global precision oncology adoption. The company is recognized for its excellence in precision medicine, driving advancements in cancer diagnosis through its extensive collaboration with pharmaceutical companies. For more information, please visit [www.amoydiagnostics.com](http://www.amoydiagnostics.com).

### **About Precision Medicine Asia (PREMIA)**

PREMIA offer an integrated platform for the development of innovative oncology therapies and diagnostics in Asia, the fastest growing market for the pharmaceutical industry. PREMIA also manages a [clinical-genomic lung cancer registry](#), the largest in the region, which includes more than 20,000 patients and allows an efficient patient identification process for clinical trial enrollment through participation by more than 200 hospitals in Japan, Taiwan, Malaysia and Thailand. For more information, please visit [www.premia-inc.com](http://www.premia-inc.com)

**Contacts:**

**Tatsuro Saito**

General Manager, Marketing department

Tel: +81-3-5759-6042

[info2@rikengenesis.jp](mailto:info2@rikengenesis.jp)



**Robson Ee**

Director, International Business

[Info@amoydiagnostics.com](mailto:Info@amoydiagnostics.com)



**Vivian Liu**

Director, Corporate Operations

Tel: 852-3978-2288

[vliu@premia-inc.com](mailto:vliu@premia-inc.com)

